Novavax Inc
NASDAQ:NVAX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.76
20.97
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NVAX stock under the Base Case scenario is 7.4 USD. Compared to the current market price of 9.32 USD, Novavax Inc is Overvalued by 21%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Novavax Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NVAX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Novavax Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Novavax Inc
Balance Sheet Decomposition
Novavax Inc
Current Assets | 1.1B |
Cash & Short-Term Investments | 909.5m |
Receivables | 95m |
Other Current Assets | 99.2m |
Non-Current Assets | 608.8m |
PP&E | 451.5m |
Intangibles | 126.8m |
Other Non-Current Assets | 30.5m |
Current Liabilities | 1.2B |
Accounts Payable | 57.5m |
Accrued Liabilities | 218.7m |
Other Current Liabilities | 904.8m |
Non-Current Liabilities | 1.1B |
Long-Term Debt | 223.6m |
Other Non-Current Liabilities | 834.3m |
Earnings Waterfall
Novavax Inc
Revenue
|
885.2m
USD
|
Cost of Revenue
|
-320.5m
USD
|
Gross Profit
|
564.6m
USD
|
Operating Expenses
|
-854.7m
USD
|
Operating Income
|
-290m
USD
|
Other Expenses
|
5.2m
USD
|
Net Income
|
-284.9m
USD
|
Free Cash Flow Analysis
Novavax Inc
USD | |
Free Cash Flow | USD |
NVAX Profitability Score
Profitability Due Diligence
Novavax Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Novavax Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
NVAX Solvency Score
Solvency Due Diligence
Novavax Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Novavax Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVAX Price Targets Summary
Novavax Inc
According to Wall Street analysts, the average 1-year price target for NVAX is 17.75 USD with a low forecast of 9.09 USD and a high forecast of 26.25 USD.
Dividends
Current shareholder yield for NVAX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NVAX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 1,541 full-time employees. The firm promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
Contact
IPO
Employees
Officers
The intrinsic value of one NVAX stock under the Base Case scenario is 7.4 USD.
Compared to the current market price of 9.32 USD, Novavax Inc is Overvalued by 21%.